Benzodiazepines, Urine Screen with Reflex to Quantitation
2012225
Ordering Recommendation
Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out benzodiazepine exposure. For follow-up testing of a presumptive result, Benzodiazepines, Urine Quantitative (2008291) is preferred.
Mnemonic
BENZ RFX U
Methodology
Qualitative Enzyme Immunoassay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Collect
- Random urine.
- Specimen Preparation
- Transfer 4 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 2 mL)
- Storage/Transport Temperature
- Room Temperature
- Unacceptable Conditions
- Breast Milk. Pharmaceutical preparation. Specimens exposed to repeated freeze/thaw cycles.
- Remarks
- Stability
- Ambient: 1 week; Refrigerated: 1 month; Frozen: 3 years
Reference Interval
Screen cutoff concentration: 200 ng/mL
Interpretive Data
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
For medical purposes only; not valid for forensic use.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
If the specimen screens positive, then Confirmation/Quantitation by LC-MS/MS (ARUP test code 2008291) will be added to confirm result. Additional charges apply.
Hotline History
View Hotline History
CPT Code(s)
80307; if reflexed, add 80346 (Reflexed Alt Code: G0480 )
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0092197 | Benzodiazepines, Urn, Screen | 19284-9 |
| 2012212 | Screen, Urine Interpretation | 54247-2 |
Aliases
- Pain Management, Benzodiazepines, Quantitative, w/ medMATCH, Urine (Drugs of Abuse Confirmation/Quan
- Pain Management, Benzodiazepines, w/Confirmation w/med MATACH, Urine (Drugs of Abuse Confirmation/Qu